Supplier
American Outcomes Management LP
American Outcomes Management LP was paid $4.96M by Medicaid between Jan 2018 and Dec 2024, across 13 billing codes. Its largest line is J1599, Injection, immune globulin, intravenous, non-lyophilized (e.g., liquid), not otherwise specified, 500 mg — 44% of everything it billed.
33Billing provider infoAMERICAN OUTCOMES MANAGEMENT LP
BROOKLYN, NY 11232
BROOKLYN, NY 11232
33aNPI1386782555assigned 02/01/2007
33bProvider typeHome Infusion Therapy Pharmacy
28Total paid$4.96M
24GClaims19,935
24DCodes billed13
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Home Infusion Therapy Pharmacy providers in New York
Rank by total paid#3 of 11
Median peer was paid$207K
This provider vs. median24×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 822 | $85K | |
| 2019 | 1,849 | $1.80M | |
| 2020 | 1,532 | $721K | |
| 2021 | 2,007 | $193K | |
| 2022 | 3,504 | $517K | |
| 2023 | 4,777 | $568K | |
| 2024incomplete | 5,444 | $1.07M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| J1599 | Injection, immune globulin, intravenous, non-lyophilized (e.g., liquid), not otherwise specified, 500 mg | 44% | 250 | 124 | $2.20M |
| 99602 | Nursing care in home rn | 17% | 5,422 | 2,865 | $839K |
| J3380 | Injection, vedolizumab, intravenous, 1 mg | 14% | 101 | 93 | $681K |
| 99601 | 11% | 6,743 | 3,530 | $560K | |
| J1459 | Injection, immune globulin (privigen), intravenous, non-lyophilized (e.g., liquid), 500 mg | 4.7% | 82 | 24 | $231K |
| S9338 | Home infusion therapy, immunotherapy, administrative services, professional pharmacy services, care coordination, and all necessary supplies and equipment (drugs and nursing visits coded separately), per diem | 4.3% | 4,221 | 2,343 | $213K |
| Q5103 | Injection, infliximab-dyyb, biosimilar, (inflectra), 10 mg | 2.2% | 47 | 46 | $111K |
| S9374 | Home infusion therapy, hydration therapy; one liter per day, administrative services, professional pharmacy services, care coordination, and all necessary supplies and equipment (drugs and nursing visits coded separately), per diem | 1.6% | 1,925 | 876 | $79K |
| S9490 | Home infusion therapy, corticosteroid infusion; administrative services, professional pharmacy services, care coordination, and all necessary supplies and equipment (drugs and nursing visits coded separately), per diem | <1% | 280 | 227 | $16K |
| S9379 | Home infusion therapy, infusion therapy, not otherwise classified; administrative services, professional pharmacy services, care coordination, and all necessary supplies and equipment (drugs and nursing visits coded separately), per diem | <1% | 315 | 269 | $12K |
| A4222 | Infusion supplies for external drug infusion pump, per cassette or bag (list drugs separately) | <1% | 270 | 232 | $12K |
| A4221 | Supplies for maintenance of non-insulin drug infusion catheter, per week (list drugs separately) | <1% | 254 | 232 | $3K |
1 more codes
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 25 | $3K |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialKRIETE, BRIAN (CHIEF FINANCIAL OFFICER)